N4 Pharma (LON:N4P) Announces Quarterly Earnings Results

N4 Pharma (LON:N4P) released its quarterly earnings results on Monday. The company reported GBX (0.31) ($0.00) EPS for the quarter, Digital Look Earnings reports. N4 Pharma had a negative return on equity of 90.68% and a negative net margin of 18,399.86%.

N4 Pharma Stock Performance

LON N4P opened at GBX 0.50 ($0.01) on Monday. The stock has a market cap of £2.15 million, a PE ratio of -1.44 and a beta of -0.37. N4 Pharma has a 12 month low of GBX 0.35 ($0.00) and a 12 month high of GBX 0.80 ($0.01). The company’s 50-day moving average price is GBX 0.45 and its 200-day moving average price is GBX 0.54.

N4 Pharma Company Profile

N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.